相关实验视频
Updated: Jul 15, 2025

06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
920
提格环素在接受抗血栓治疗的患者中的安全性:单中心回顾性研究
Chuwen Lin1, Miaoqin Tan1, Dongmei Wang1
1Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Pharmacology
|September 26, 2023
概括
长时间治疗tigecycline, cefoperazone/sulbactam和低基线纤维素因子会增加低纤维素因子症的风险. 结合tigecycline和抗血栓药物并不会使出血事件恶化.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
- 传染性疾病 传染性疾病
背景情况:
- 提格环素是一种用于严重感染的抗生素.
- 低纤维素生成血是tigecycline治疗的潜在副作用之一.
- 结合tigecycline与抗血栓药物的安全性需要调查.
研究的目的:
- 为了识别tigecycline诱导的低纤维素生成血的危险因素.
- 评估tigecycline和抗血栓剂同时使用的安全性.
主要方法:
- 对68名接受tigecycline超过3天的患者进行了回顾性分析.
- 收集的数据包括纤维素水平,tigecycline剂量和持续时间,疾病严重程度和实验室参数.
- 用单变量和多变量方法分析了低纤维素生成血的危险因素. 在接受抗血栓药物治疗的患者和未接受抗血栓药物治疗的患者之间比较了出血事件.
主要成果:
- 在68名患者中,有20名患者出现过低纤维素生成血症.
- 风险因素包括更长的治疗时间,塞福拉/苏尔巴克坦组合,以及较低的治疗前纤维素水平.
- 在接受tigecycline与抗血栓药物或不接受抗血栓药物的患者之间,没有观察到血红蛋白下降或红细胞输血需求的显著差异.
结论:
- 延长的tigecycline治疗,并发的 cefoperazone/sulbactam,以及较低的初始纤维素原水平,都与低纤维素原血症的风险增加有关.
- 与tigecycline同时使用抗血栓药物似乎不会增加出血风险.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Therapeutic Index
4.3K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
552
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
552
Anticoagulant Drugs: Low-Molecular-Weight Heparins
741
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
741
Venous Thrombosis IV: Nursing Management
14
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
14

